During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.

NEW YORK, NY / ACCESSWIRE / October 24, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

With the $2.8 billion acquisition deal of California's Genomic Health officially completed, Madison-based Exact Sciences Corp. is calculating the estimated combined revenues earned by both companies for the recent fourth quarter.

Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REDWOOD CITY, Calif., Nov. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (GHDX) announced that its stockholders voted to approve the company's proposed combination with Exact Sciences Corp (EXAS) at a special meeting held earlier today. As previously announced, on July 29, 2019, Genomic Health and Exact Sciences entered into the merger agreement by which Exact Sciences will acquire Genomic Health in a cash and stock transaction. With the receipt of the required stockholder approval, Genomic Health and Exact Sciences expect to close the transaction on Friday, November 8 subject to satisfaction of the remaining customary closing conditions.

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NEW YORK , Nov. 4, 2019 /PRNewswire/ -- Shenandoah Telecommunications Co. (NASD: SHEN) will replace Genomic Health Inc. (NASD: GHDX) in the S&P SmallCap 600 effective prior to the open of trading on Friday, ...

REDWOOD CITY, Calif., Sept. 30, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from a new analysis of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which reinforce the unique value of the Oncotype DX Breast Recurrence Score® test to guide the use of adjuvant chemotherapy for women with hormone receptor-positive (HR+), HER2-negative, early-stage breast cancer and identify those patients who derive a significant benefit from treatment. The findings, published today in JAMA Oncology1 and presented at the ESMO 2019 Congress2, are consistent with results from the B20 trial3 and show that, in patients with high Recurrence Score results (26-100) treated with endocrine therapy plus chemotherapy, outcomes were better compared to what would be expected with endocrine therapy alone.

NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers ...

Genomic Health chairman and CEO Kim Popovits is leaving the company as part of the combination of the two companies.

In the weeks leading up to unveiling a $2.8 billion cash-and-stock merger — and especially in the final few days — top executives and directors of Genomic Health Inc. were locked in a fierce back-and-forth with Exact Sciences Corp. that at one point led the pioneering Redwood City-based cancer test maker to reject the deal. In a Securities and Exchange Commission filing late Friday ahead of a Nov. 7 shareholder vote on the deal, Genomic Health (NASDAQ: GHDX) said its board rejected Madison, Wisconsin-based Exact Sciences' (NASDAQ: EXAS) offer before ultimately agreeing to a $72-per-share price. Midway through negotiations, a financial adviser reached out to Genomic Health on behalf of an "unnamed strategic player" based outside the United States that was in the early stages of considering delving into the U.S. health care market via a transaction.

HTEC is poised to benefit from rapid advances in health-care technology

There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 3:19-cv-05929-SI, on behalf of shareholders of Genomic Health, Inc. ("Genomic" or the "Company") (GHDX) who have been harmed by Genomic's and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with Exact Sciences Corporation ("Exact Sciences") (the "Proposed Transaction").

NEW YORK, NY / ACCESSWIRE / September 26, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in ...

NEW YORK, NY / ACCESSWIRE / October 10, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

Chairman and CEO Kim Popovits has been in various leadership positions with the Redwood City company since 2002.

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

MADISON, Wisconsin, Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy, chairman and CEO of Exact Sciences. "We're excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along their cancer journey.

Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.